Page 2 - Multiple Sclerosis Program News Today

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohns Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody ... | March 25, 2022

This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022.NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough...

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under

COVID-19 pandemic has created major changes in delivery of MS care A survey of U.S. multiple sclerosis, or MS, specialist clinicians reveals the COVID-19 pandemic has created major changes in how they deliver care. "Since the pandemic began, more than 95% of our survey respondents reported using telehealth platforms to provide care for their patients," said Dr. Elizabeth Morrison-Banks, a health sciences clinical professor of neurology in the School of Medicine at the University of California, ...

 E-Mail IMAGE: Dr. Elizabeth Morrison-Banks is a health sciences clinical professor of neurology at UC Riverside. view more  Credit: C. Rosema. RIVERSIDE, Calif. -- A survey of U.S. multiple sclerosis, or MS, specialist clinicians reveals the COVID-19 pandemic has created major changes in how they deliver care. "Since the pandemic began, more than 95% of our survey respondents reported using telehealth platforms to provide care for their patients," said Dr. Elizabeth Morrison-Banks, a...